The University of Western Australia

A study published in The Lancet Respiratory Medicine suggests benralizumab, an injection, may be a breakthrough treatment for asthma and COPD flare-ups, reducing treatment failure rates and side-effects compared to steroids. The trial showed 45% treatment failure with benralizumab versus 74% with prednisolone, with faster symptom recovery and improved quality of life. Phase 3 trials are needed for approval.